Clinical & Translational Oncology最新文献

{"title":"Genomic alteration correlates with programmed cell death ligand 1 (PD-L1) expression in 2750 Chinese non-small-cell lung cancer patients.","authors":"Xiaohong Duan, Dawei Sun, Siyao Liu, Junyan Su, Jiali Zhang, Mengyuan Liu, Ning Li, Ou Qiao, Zichuan Liu, Yanhua Gong","doi":"10.1007/s12094-025-03966-2","DOIUrl":"https://doi.org/10.1007/s12094-025-03966-2","url":null,"abstract":"<p><strong>Background: </strong>This study sought to identify new biomarkers by examining genomic profiling and PD-L1 expression. While the PD-L1 and tumor mutational burden (TMB) are currently the main clinically available biomarkers for predicting immunotherapy response in non-small-cell lung cancer (NSCLC), the factors that affect PD-L1 expression remain unclear.</p><p><strong>Materials and methods: </strong>This retrospective study included tumor and blood samples from 2750 Chinese patients with NSCLC who had successful PD-L1 assessments and targeted next-generation sequencing. Clinicopathological characteristics and genomics profile were analyzed. TMB was categorized as high (TMB-H) if there were ≥ 10 mutations per megabase. PD-L1 expression was classified into three groups: PD-L1-negative, PD-L1-low, and PD-L1-high. In addition, genomic data, and immune checkpoint inhibitor (ICI) outcomes for 197 NSCLC patients were obtained from the MSK2020 cohort.</p><p><strong>Results: </strong>This study included a total of 2750 NSCLC cases. Tumors with high PD-L1 expression were more commonly observed in males and exhibited a higher median TMB. Significant differences in gene mutation frequencies were observed among the different PD-L1 expression groups. Significant differences in mutation frequencies were observed in PD-L1 expression subgroups for the EGFR, TP53, LRP1B, KRAS, SPTA1, and PTPRD genes. Notably, TP53 and KRAS alterations were significantly enriched in PD-L1-high subgroup, while EGFR mutations were associated with PD-L1 negativity. Patients in the PD-L1-high group showed notably improved progression-free survival (PFS) and overall survival (OS) compared to those in the PD-L1-low and negative groups. Further analysis of the combined impact of PD-L1 expression and TMB revealed that the PD-L1-negative/TMB-low subgroup had significantly shorter PFS and OS compared to the other subgroups. This indicates that a composite biomarker combining PD-L1 expression and TMB provides superior predictive value for favorable ICI outcomes.</p><p><strong>Conclusions: </strong>This study indicates that PD-L1 expression levels are significantly associated with specific genomic alterations and clinical outcomes in patients with NSCLC. Particularly in evaluating the efficacy of ICI therapy, the combined biomarker of PD-L1 and TMB shows important clinical application value.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).","authors":"Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma","doi":"10.1007/s12094-025-03941-x","DOIUrl":"https://doi.org/10.1007/s12094-025-03941-x","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy-associated mutational process signature and genomic alterations associated with outcome in metastatic pancreatic cancer.","authors":"Kaiqiang Wang, Linqiang Zhang, Qingkui Li, Qinghua Wang, Zhijia Jiang, Yaqing Wei, Tonghe Zhang, Zhaoyang Li, Zhan Jiang, Huitang Yang, Yandong Cai, Guoju Fan, Bo Chen, Hongwei Zhang, Yankui Li, Jinjin Sun","doi":"10.1007/s12094-025-03975-1","DOIUrl":"https://doi.org/10.1007/s12094-025-03975-1","url":null,"abstract":"<p><strong>Objective: </strong>Metastatic pancreatic cancer (mPAC) carries a dismal prognosis, and effective prognostic biomarkers are critically needed. This study aims to explore novel molecular prognostic markers for mPAC from the perspective of somatic mutations.</p><p><strong>Methods: </strong>We integrated clinical data and somatic mutation profiles from 820 mPAC patients. Prognosis-associated molecular markers were systematically explored from three perspectives: mutational process signatures, mutation activity-driven molecular subtypes, and genomic variations.</p><p><strong>Results: </strong>The median overall survival was 11.1 months (95% CI: 9.92-12.6). Liver metastasis was the most common site and associated with worse prognosis. Tumor mutational burden (TMB) and fraction genome alteration (FGA) were favorable prognostic biomarkers. Non-negative matrix factorization identified three distinct mutational process signatures (SBS1, SBS11, and SBS29). Notably, the presence of the temozolomide-associated signature (SBS11, characterized by C > T substitutions) was associated with improved survival. Consensus clustering of mutational activity defined seven molecular subtypes, one of which (Cluster 4) demonstrated the most favorable prognosis. Genomic profiling revealed that patients harboring KRAS p.G12V mutations had the poorest survival outcomes and significantly reduced immunogenicity. Furthermore, copy-number deletions in KRAS, AKT2, and MYC were identified as biomarkers of adverse prognosis.</p><p><strong>Conclusions: </strong>By deciphering the somatic mutational landscape of mPAC, this study identified potential molecular biomarkers associated with survival outcomes, providing a scientific foundation for prognostic prediction and informing clinical treatment strategies for mPAC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiota interaction with Tregs: a target for colitis.","authors":"Keywan Mortezaee","doi":"10.1007/s12094-025-03974-2","DOIUrl":"https://doi.org/10.1007/s12094-025-03974-2","url":null,"abstract":"<p><p>Gut-resident microbiota associate with host immune system to promote homeostasis, and regulatory T cells (Tregs) are critical in the maintenance of immune balance. Tregs have immunosuppressive activity, and their presence hampers the development of inflammatory diseases. This review aims to unravel microbiome impact on Tregs in bowel inflammation and harnessing such interaction to combat colitis as a separate disease or a consequence of immune checkpoint inhibitor (ICI) therapy of cancer. Short-chain fatty acids (SCFAs) are microbial-derived metabolites associated positively with Treg generation and maintenance and being effective for hampering bowel inflammation. Treg induction shapes gut microbiota profile and support microorganism colonization in their niche and protect the host from inflammation, while suppression of Treg differentiation and activity directs microbiota-induced Th17 expansion and inducing inflammation. Thus, balancing Treg representation with Th17 cells and Treg reprogramming through manipulation of gut microbiota can offer therapy. Microbiota epithelial attachment/detachment and interaction with antigen-presenting cells (APCs) are important for the final fate of T cell signature. Fecal microbial transplantation (FMT) is a strategy for promoting normobiosis and represents a navel approach to targeting colitis. FMT with appropriate microbiota from healthy donors can reinforce microbial diversity, density and persistence to enrich their environment with transforming growth factor (TGF)-β, induce IL-10 producing APCs and reinforce gut barrier, with all these being effective for recovering Tregs, restoring intestinal homeostasis and hampering colitis. ICI therapy of cancer may predispose subjects to colitis due to the impact on microbiome and reducing Treg population. FMT promotes local Treg reorchestration, being advantageous in cancer patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UGT1A6 in pancreatic cancer: a promising prognostic biomarker and therapeutic target.","authors":"Xue-An Lu, Yan-Nan Pan, Chen-Jun Xie, Qing-Wen Wang, Shi-Wei Xu, Qin Wang, Youzhao He, Lei-Sheng Wang, Yong Mao, Hao Hu","doi":"10.1007/s12094-025-03976-0","DOIUrl":"https://doi.org/10.1007/s12094-025-03976-0","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the role of the UDP glucuronosyltransferase 1 family, polypeptide A6 (UGT1A6), in pancreatic cancer, focusing on its expression patterns, clinical significance, impact on tumor progression, and potential involvement in immune evasion.</p><p><strong>Methods: </strong>UGT1A6 expression across multiple cancer types was analyzed using TNMplot, GEPIA, and The Cancer Genome Atlas (TCGA) databases. Functional experiments, including western blotting, qRT-PCR, CCK-8, and Transwell assays, were performed on pancreatic cancer cell lines to assess their proliferation and migration capabilities. Single-cell data and cell-cell communication analyses using CellChat were conducted to investigate UGT1A6's influence on the immune microenvironment.</p><p><strong>Results: </strong>UGT1A6 expression was significantly upregulated in pancreatic cancer tissues and correlated with poor overall survival (P = 0.0095), advanced TNM stage, and KRAS and TP53 mutations. Functional experiments revealed that UGT1A6 knockdown markedly suppressed the proliferation and migration of pancreatic cancer cells. Immune analysis demonstrated a positive correlation between UGT1A6 and immunosuppressive molecules (CD274, PDCD1LG2, HAVCR2, and TGFBR1) and specific immune cell infiltration patterns, indicating a potential role in promoting immune evasion. Single-cell analysis further showed enhanced communication between UGT1A6-expressing tumor epithelial cells and immune cells, which might impair antitumor immune responses.</p><p><strong>Conclusion: </strong>UGT1A6 acts as a key driver of pancreatic cancer progression and immune evasion, and is emerging as a promising prognostic biomarker and therapeutic target. Future studies should focus on clarifying the detailed molecular mechanisms and validating their clinical utility in precision therapy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in molecular mechanisms of microRNAs in pathogenesis and resistance of treatment in glioblastoma.","authors":"Siddharth Shah, Sai Lavanya Patnala, Mihit Kalawatia, Brandon Lucke-Wold","doi":"10.1007/s12094-025-03969-z","DOIUrl":"https://doi.org/10.1007/s12094-025-03969-z","url":null,"abstract":"<p><p>Glioblastoma (GBM) is the most aggressive brain cancer with poor prognosis, even with current treatments combining surgery, chemotherapy, and radiation. Despite initial tumor removal, recurrence is common and driven by altered genetic profiles. MicroRNAs (miRNAs), small non-coding RNAs with regulatory roles, are implicated in GBM progression through their influence on key hallmarks such as angiogenesis, proliferation, immune evasion, and resistance to therapy. This review systematically analyzed peer-reviewed literature from 2019 to 2025 to evaluate recent findings on miRNAs in GBM pathogenesis. Studies reveal differential miRNA expression in GBM models and their involvement in tumor biology via modulation of target genes. Understanding miRNA networks, along with the tumor microenvironment and immune interactions, may enable the identification of diagnostic and therapeutic biomarkers. Targeting both tumor and associated immune components presents a promising direction for future GBM therapies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myeloid-derived suppressor cells modulation in the context of tumor microenvironment for gastric cancer.","authors":"José Dario Portillo-Miño, Jhon Jairo Calderón, Erika Ruiz-García, Cecilia Monge","doi":"10.1007/s12094-025-03960-8","DOIUrl":"https://doi.org/10.1007/s12094-025-03960-8","url":null,"abstract":"<p><p>Gastric cancer (GC) exhibits aggressive behavior and high mortality rates globally. In this respect, the effectiveness of chemotherapy and immunotherapy is hindered by various factors including tumor heterogeneity, immune phenotypes, chronic H. pylori infection, and an immunosuppressive tumor microenvironment (TME). The immunosuppressive TME is fostered by multiple immune cell subpopulations as tumor-associated neutrophils, tumor-associated macrophages, tumor-associated dendritic cells, regulatory T cells, and myeloid-derived suppressor cells (MDSCs). The MDSC abundantly infiltrates gastric TME, which interacts with H. pylori infection and is influenced by reactive oxygen species (ROS), chronic inflammation, and hypoxia. Understanding its cellular and molecular biology of GC is crucial for developing novel therapeutic options. Current preclinical evidence is emerging to support translational oncology on MDSC immunotherapy. This article review suggests MDSC modulation may be a promising avenue for enhancing chemotherapy and immunotherapy responses against GC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impact following the establishment of a specialized brain metastases tumor board.","authors":"Izaskun Valduvieco, Gabriela Antelo, Alberto Di Somma, Mireia Alvarez, Sebastian Capurro, MLourdes Olondo, Ana Arance, Laura Ferrer-Mileo, Iban Aldecoa, Carme Ares, Tanny Barreto, Alejandra Mosteiro, Josep Gonzalez, Joaquim Enseñat, Meritxell Mollà","doi":"10.1007/s12094-025-03949-3","DOIUrl":"https://doi.org/10.1007/s12094-025-03949-3","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the impact of brain metastasis tumor board (BMTB) on treatment patterns and survival.</p><p><strong>Methods: </strong>365 patients with brain metastases (BM) were analyzed at the Hospital Clínic de Barcelona from October 2019 to October 2022. This included those treated in the department of neurosurgery and radiation oncology during the first 18 months following its establishment. Demographic, clinicopathological, and treatment data were recorded and compared between the groups with and without BTBM.</p><p><strong>Results: </strong>Of 365, 95 were in the BMTB group and 270 in the non-BMTB group. Patients discussed at the BMTB had higher rates of surgery (53.7% vs. 14.7%, p < 0.001) and stereotactic radiosurgery (63.1% vs. 21.6%, p < 0.001). The time between surgical treatment and adjuvant radiotherapy was shorter in the BMTB group (37 days, 95% CI 4 vs. 48 days, 95% CI 18, p = 0.018). No differences were observed in local progression (26.0% vs. 20.8%, p = 0.9) but there were differences in cerebral progression (43.2% vs. 27.4%, p = 0.004). Rescue treatment was more common in the BMTB group (26.3% vs 10.0%, p < 0.001). Median survival after BM was significantly longer in the BMTB group (28.2 ± 2.7 vs. 12.7 ± 1.04 months, p < 0.001).</p><p><strong>Conclusion: </strong>Multidisciplinary discussions for patients with BM are crucial as they improve overall survival through integrated therapies. Additional trials are needed to optimize treatment integration in this complication.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a practice-based score to predict extended duration of proton beam therapy session in pediatric patients.","authors":"José M Fernández-de Miguel, Miguel Ángel García-Aroca, Ignacio Manrique Yera, Felipe A Calvo, María Aymerich de Francesci, Jose Manuel Álvarez Avello, Elena Panizo Morgado, Jorge M Núñez-Córdoba","doi":"10.1007/s12094-025-03972-4","DOIUrl":"10.1007/s12094-025-03972-4","url":null,"abstract":"<p><strong>Purpose: </strong>Due to the labor intensity demanded by proton beam therapy (PBT) in pediatric patients, information on operational procedures related to efficiency is crucial to optimize quality and safety. We aimed to identify patient factors that affect the duration of the pediatric PBT session and to develop an easy-to-use predictive score of extended duration.</p><p><strong>Methods/patients: </strong>This is an observational retrospective cohort study in an academic medical centre, between May 2020 and February 2024. Seventy seven ASA III pediatric patients treated with PBT were recruited.</p><p><strong>Results: </strong>The mean age was 4.8 years [standard deviation (SD): 2.1] and 52% were women. The mean duration of the PBT session was 50 min (SD: 17). Extended duration of the PBT session (> 45 min) occurred in 39 patients (51%). Five predictors of extended duration were selected for the final prediction model. In the multivariable model, an age > 45 months showed a near eightfold increased odds of extended duration [Odds ratio (OR): 7.76, 95% confidence interval (95% CI) 1.63-36.99, P = 0.010]. The OR (95% CI) for long-term venous access, no recurrent tumors, hydrocephalus, and craniospinal location were 5.91 (1.47 to 23.79), 3.81 (0.67 to 21.69), 3.79 (0.90 to 15.97), and 2.59 (0.69 to 9.76), respectively. This five-variable model was used to build a nomogram-based score with an area under the receiver operating characteristic curve of 0.84 (95% CI 0.76-0.93).</p><p><strong>Conclusions: </strong>A simple nomogram based on readily available pretreatment data has potential for planning pediatric PBT standard clinical expert practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal inference in the diagnosis and prognosis of ovarian cancer: current state and future directions.","authors":"Feng Zhan, Lidan He, Shilong Qin, Yina Guo","doi":"10.1007/s12094-025-03967-1","DOIUrl":"10.1007/s12094-025-03967-1","url":null,"abstract":"<p><p>Ovarian cancer represents one of the most lethal gynecologic malignancies, characterized by low early detection rates and challenging prognostic assessment. Conventional diagnostic modalities demonstrate limited sensitivity and specificity for early-stage disease identification. Recent research has begun to explore causal inference methodologies as complementary approaches that may enhance diagnostic precision and prognostic capability. This systematic review evaluates the current state and future prospects of causal inference methodologies in enhancing ovarian cancer diagnosis and prognosis. We performed a comprehensive systematic review focusing on causal inference methodologies applied to ovarian cancer research. The analysis encompassed biomarker identification, pathogenic mechanism elucidation, and multimodal data integration. Additionally, we analyzed the synergistic combination of causal inference with machine learning approaches across genomic, transcriptomic, proteomic, and imaging datasets. Causal inference methods have shown effectiveness in identifying crucial biomarkers and revealing underlying pathogenic mechanisms of ovarian cancer. The integration of machine learning with causal inference has enhanced model interpretability, clinical applicability, and diagnostic-prognostic accuracy. These approaches have achieved improved predictions of disease progression and optimization of treatment strategies by leveraging clinical, genetic, and imaging data. Causal inference shows considerable potential in advancing precision medicine for ovarian cancer, offering robust frameworks for addressing confounding factors and establishing causal relationships. As these methodologies evolve and data volumes expand, their application may become increasingly valuable in oncology practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}